Summary: This presentation introduces a systematic, data-driven approach for assessing the developability of biologic therapeutics, with a focus on pre-formulation development.

Summary: Catalent’s advanced iPSC-based platforms offer GMP-ready solutions for gene editing and cell differentiation, enabling partners to streamline therapeutic development.

The cell line development technology platform revolutionizes the generation of complex biologics with unmatched speed, scalability, and flexibility.

Autologous cell therapies promise life-changing treatments but face steep barriers in scalability, cost, and reliability.

Summary: Characterizing molecular stability early is critical to advancing biologics through development and into the clinic.

In this webinar, Pedro Morales, Director and Scientific Advisor at Catalent, showcases how the Kansas City site delivers tailored analytical solutions to support biologics development from discovery through commercialization.

Plasmid DNA is a vital component in the production of viral and nonviral cell and gene therapies (CGT). Catalent's innovative UpTempo℠ Plasmid Platform Process has revolutionized plasmid DNA manufacturing by addressing key challenges and significantly reducing development time.

Catalent Biologics’ Limoges, France development center is our European center of excellence for early phase clinical biologics formulation development and drug product fill/finish.

Catalent’s mammalian cell line engineering and biomanufacturing capabilities, utilizing single-use systems, provide the flexibility and scalability needed to support our customers' growth.

Forced degradation studies are essential to the successful development of monoclonal antibodies (mAbs), bispecifics, and other biologics.